Cancer biotech Chimeric soars 50pc on debut

Champagne corks are flying for investors in emerging cancer therapy company Chimeric Therapeutics, which had a stellar start to listed life, thanks to its shares soaring more than 60 per cent in opening trade.

The business has just begun a phase-one clinical trial of its CAR-T therapy for recurrent glioblastoma (brain cancer) in the US, having successfully licensed the early-stage therapy from the Los Angeles-based City of Hope cancer treatment and research centre.